Co-delivery of a hydrophobic small molecule and a hydrophilic peptide by porous silicon nanoparticles

Liu, Dongfei; Bimbo, Luís M.; Mäkilä, Ermei; Villanova, Francesca; Kaasalainen, Martti; Herranz-Blanco, Bárbara; Caramella, Carla; Lehto, Vesa‐Pekka; Salonen, Jarno; Herzig, Karl‐Heinz; Hirvonen, Jouni; Santos, Hélder A.

doi:10.1016/j.jconrel.2013.05.036

Cited by 143 publications

(104 citation statements)

References 64 publications

Supporting

Mentioning

103

Contrasting

Order By: Relevance

“…PSi has also been shown to be capable to carry different molecules simultaneously (Liu et al, 2013a). Loading capacity determining factors from previous studies are summarized in Table 8.…”

Section: B Porous Silicon As a Peptide Delivery Systemmentioning

confidence: 99%

Novel Delivery Systems for Improving the Clinical Use of Peptides

et al. 2015

Self Cite

View full text Add to dashboard Cite

“…PSi has also been shown to be capable to carry different molecules simultaneously (Liu et al, 2013a). Loading capacity determining factors from previous studies are summarized in Table 8.…”

Section: B Porous Silicon As a Peptide Delivery Systemmentioning

confidence: 99%

Novel Delivery Systems for Improving the Clinical Use of Peptides

et al. 2015

Self Cite

View full text Add to dashboard Cite

“…67 Chemical engineers have thus far addressed problems of drug 68 delivery control in hydrogel-based drug delivery systems by 69 designing nanodomain-structured materials, such as block copoly-70 mers, that bind to drug molecules through electrostatic [4,5] and 71 covalent bonds [6,7] as well as hydrophobic interactions [8,9], 72 delaying diffusion of the drug out of the material. More complex 73 assemblies combining electrostatic and hydrophobic interactions 74 have been developed to co-deliver hydrophilic and hydrophobic 75 drugs [10][11][12][13] to thereby trigger drug synergy or suppress drug 76 resistance. For example, co-delivery of paclitaxel with an inter-77 leukin-12-encoded plasmid by nanoparticles suppresses cancer 78 growth more effectively than the paclitaxel or the plasmid alone 79 [13].…”

mentioning

confidence: 99%

Covalently-crosslinked mucin biopolymer hydrogels for sustained drug delivery

2015

View full text Add to dashboard Cite

The sustained delivery of both hydrophobic and hydrophilic drugs from hydrogels has remained a challenge requiring the design and scalable production of complex multifunctional synthetic polymers. Here, we demonstrate that mucin glycoproteins, the gel-forming constituents of native mucus, are suitable for assembly into robust hydrogels capable of facilitating the sustained release of hydrophobic and hydrophilic drugs. Covalently-crosslinked mucin hydrogels were generated via exposure of methacrylated mucin to ultraviolet light in the presence of a free radical photoinitiator. The hydrogels exhibited an elastic modulus similar to that of soft mammalian tissue and were sensitive to proteolytic degradation by pronase. Paclitaxel, a hydrophobic anti-cancer drug, and polymyxin B, a positively-charged hydrophilic antibacterial drug, were retained in the hydrogels and released linearly with time over seven days. After four weeks of drug release, the hydrogels continued to release sufficient amounts of active paclitaxel to reduce HeLa cell viability and sufficient amounts of active polymyxin B to prevent bacterial proliferation. Along with previously-established anti-inflammatory, anti-viral, and hydrocarbon-solubilizing properties of mucin, the results of this study establish mucin as a readily-available, chemically-versatile, naturally-biocompatible alternative to complex multifunctional synthetic polymers as building blocks in the design of biomaterials for sustained drug delivery.

show abstract

“…Since the first report revealing porous silicon particles-induced enhancement of paracellular delivery of insulin [25], sufficient advancement in developing pSi-based effective drug delivery systems for various kinds of therapeutic agents (e.g., pharmaceutical drugs (indomethacin (IMC) [26,27], doxorubicin (DOX) [28][29][30][31][32], paclitaxel [33], mitoxantrone dihydrochloride (MTX) [34,35], camptothecin (CPT) [36][37][38][39], and emodin [40]), therapeutic proteins (insulin [25,41], bovine serum albumin (BSA) [41], peptide [26,[42][43][44][45][46] ), and genes (siRNA [33,[47][48][49][50]), etc.) has been achieved in recent decades.…”

Section: Drug Deliverymentioning

confidence: 99%

“…In 2012, Kaasalainen et al studied the influence of medium composition (gastrointestinal peptides GLP-1 (7-37) and PYY (3-36)) on the zeta potential of pSi nanoparticles [43]. After that, Liu et al for the first time introduced another kind of pSi-based carriers capable of co-loading a hydrophobic drug (IMC) and a hydrophilic peptide (PTT 3-36) [26]. In the same year, Kovalainen et al prepared pSi nanoparticles loaded with a hydrophilic peptide (PYY3-36), which were workable for achieving a high peptide loading degree and sustained in vivo PYY-3-36 delivery over several days [42,46].…”

Section: Protein and Gene Deliverymentioning

confidence: 99%

Silicon-Based Nanoagents for Cancer Therapy

2014

SpringerBriefs in Molecular Science

View full text Add to dashboard Cite

Nanotechnology has emerged as highly promising tools for cancer therapy. In comparison to traditional therapeutic methods (e.g., chemotherapy and radiotherapy) generally involving limited specificity and undesired side effects, nanomaterials (e.g., magnetic nanoparticles, carbon-based nanomaterials, and porous silicon, etc.)-based nanoagents and therapeutic strategies significantly facilitate the improvement of therapeutic efficacy and reduce the toxic side effect. In particular, silicon nanomaterials featuring large surface-to-volume ratio and abundant surface chemistry open up completely new avenues for design of novel silicon-based nanoagents with large drug-loading capacity and high tumor-targeting efficacy. In the past decade, porous silicon (pSi) has been widely employed as high-performance delivery systems for different types of therapeutic drug molecules, proteins, and genes, aiming at improved therapeutic efficacy and reduced toxic side effect. The pSi can be also functionalized with photosensitizers, radiosensitizers, or heat producers, which are efficacious for phototherapy or radiotherapy of cancer. On the other hand, silicon nanowires (SiNWs) and SiNWsbased nanohybrids (e.g., gold nanoparticles/nanospheres-coated SiNWs), serving as novel classes of drug nanocarriers and hyperthermia nanoagents, have recently been explored for in vitro and in vivo cancer therapy with encouraging therapeutic outcomes.

show abstract

Co-delivery of a hydrophobic small molecule and a hydrophilic peptide by porous silicon nanoparticles

Cited by 143 publications

References 64 publications

Novel Delivery Systems for Improving the Clinical Use of Peptides

Novel Delivery Systems for Improving the Clinical Use of Peptides

Covalently-crosslinked mucin biopolymer hydrogels for sustained drug delivery

Silicon-Based Nanoagents for Cancer Therapy

Contact Info

Product

Resources

About